S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
Log in
NASDAQ:GERN

Geron Stock Forecast, Price & News

$1.74
-0.08 (-4.40 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.73
Now: $1.74▼
$1.81
50-Day Range
$1.68
MA: $1.87▼
$2.05
52-Week Range
$0.75
Now: $1.74▼
$2.40
Volume1.85 million shs
Average Volume2.64 million shs
Market Capitalization$540.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Read More
Geron logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.04 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
Previous Symbol
CUSIP37416310
CIK886744
Webwww.geron.com
Phone650-473-7700
Employees45

Debt

Debt-to-Equity RatioN/A
Current Ratio11.53
Quick Ratio11.53

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$460,000.00
Price / Sales1,174.38
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.68 per share
Price / Book2.56

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-68,550,000.00
Net Margins-19,251.64%
Return on Equity-46.39%
Return on Assets-40.90%

Miscellaneous

Outstanding Shares310,467,000
Market Cap$540.21 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$1.74
-0.08 (-4.40 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Geron (NASDAQ:GERN) Frequently Asked Questions

How has Geron's stock been impacted by Coronavirus?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN shares have increased by 68.9% and is now trading at $1.74.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Geron?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Geron.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Geron.

How can I listen to Geron's earnings call?

Geron will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. Geron had a negative return on equity of 46.39% and a negative net margin of 19,251.64%.
View Geron's earnings history.

What price target have analysts set for GERN?

6 equities research analysts have issued 1 year price objectives for Geron's shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Geron's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price.
View analysts' price targets for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in September. As of September 30th, there was short interest totaling 44,180,000 shares, an increase of 32.4% from the September 15th total of 33,360,000 shares. Based on an average trading volume of 2,940,000 shares, the days-to-cover ratio is currently 15.0 days.
View Geron's Short Interest.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Ionis Pharmaceuticals (IONS).
View all competitors.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and BioNano Genomics (BNGO).

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 69, Pay $1.15M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 51, Pay $687.17k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 56, Pay $705.69k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 56, Pay $673.36k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 45, Pay $968.2k)
  • Ms. Suzanne Messere, Head of Investor Relations & Corp. Communications
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 70)
  • Ms. Shannon Odam, VP of HR
  • Mr. Anil Kapur, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 50)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by many different retail and institutional investors. Top institutional investors include WINTON GROUP Ltd (0.02%), BNP Paribas Arbitrage SA (0.02%), Avantax Advisory Services Inc. (0.01%) and Amalgamated Bank (0.01%). Company insiders that own Geron stock include Elizabeth G O'farrell and Melissa Kelly Behrs.
View institutional ownership trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for Geron.

Which major investors are buying Geron stock?

GERN stock was acquired by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Avantax Advisory Services Inc., and Amalgamated Bank.
View insider buying and selling activity for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.74.

How big of a company is Geron?

Geron has a market capitalization of $540.21 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.